FindTrial
Sign In

Efficacy of IVIG in the treatment of treatment-resistent painful neuropathy - IVIg in neuropathic pain

Efficacy of IVIG in the treatment of treatment-resistent painful neuropathy - IVIg in neuropathic pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-007007-32-IT
Enrollment
Unknown
Registered
2008-07-15
Start date
2007-12-13
Completion date
Unknown
Last updated
2012-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painful Neuropathies MedDRA version: 9.1 Level: PT Classification code 10012680 Term: Diabetic neuropathy

Interventions

Trade Name: FLEBOGAMMA 5% Pharmaceutical Form: Solution for infusion INN or Proposed INN: Immunoglobulins, normal human, for intravascular adm. Concentration unit: g/l gram(s)/litre Concentration type

Sponsors

AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with painful neuropathy treatment resistent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients with psychiatric disorders, or with other kinds of pain (not neuropathic)

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate efficacy of IVIg in treatment resistent painful neuropathies;Secondary Objective: To evaluate tollerability of IVIg;Primary end point(s): pain intensity evaluated using VAS—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026